Phase II trial of amonafide in central nervous system tumors: A Southwest Oncology Group Study

Sarah A. Taylor; Cathryn Rankin; Jeannette J. Townsend; Johnny B. Craig; Ralph B. Vance; Dilip L. Solank; Thomas D. Brown; Kurt Jaeckle

doi:10.1023/A:1014488922368

Phase II trial of amonafide in central nervous system tumors: A Southwest Oncology Group Study

Sarah A. Taylor, Cathryn Rankin, Jeannette J. Townsend, Johnny B. Craig, Ralph B. Vance, Dilip L. Solank, Thomas D. Brown, Kurt Jaeckle

Neurology

Research output: Contribution to journal › Article

5 Scopus citations

Abstract

Amonafide 300 mg/M² was administered intravenously on a daily × 5 schedule to 27 eligible patients with recurrent or progressive central nervous system tumors. There were no objective responses. The most common toxicities were gastrointestinal, hematologic and neurologic. Further study of amonafide in patients with central nervous system malignancies is not indicated.

Original language	English (US)
Pages (from-to)	113-115
Number of pages	3
Journal	Investigational New Drugs
Volume	20
Issue number	1
DOIs	https://doi.org/10.1023/A:1014488922368
State	Published - Apr 6 2002

Fingerprint

Keywords

Amonafide
Central nervous system tumors

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

Cite this

Taylor, S. A., Rankin, C., Townsend, J. J., Craig, J. B., Vance, R. B., Solank, D. L., Brown, T. D., & Jaeckle, K. (2002). Phase II trial of amonafide in central nervous system tumors: A Southwest Oncology Group Study. Investigational New Drugs, 20(1), 113-115. https://doi.org/10.1023/A:1014488922368

@article{dfdc053f025849ea87a43562c904ae58,

title = "Phase II trial of amonafide in central nervous system tumors: A Southwest Oncology Group Study",

abstract = "Amonafide 300 mg/M2 was administered intravenously on a daily × 5 schedule to 27 eligible patients with recurrent or progressive central nervous system tumors. There were no objective responses. The most common toxicities were gastrointestinal, hematologic and neurologic. Further study of amonafide in patients with central nervous system malignancies is not indicated.",

keywords = "Amonafide, Central nervous system tumors",

author = "Taylor, {Sarah A.} and Cathryn Rankin and Townsend, {Jeannette J.} and Craig, {Johnny B.} and Vance, {Ralph B.} and Solank, {Dilip L.} and Brown, {Thomas D.} and Kurt Jaeckle",

year = "2002",

month = apr

day = "6",

doi = "10.1023/A:1014488922368",

language = "English (US)",

volume = "20",

pages = "113--115",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "1",

}

TY - JOUR

T1 - Phase II trial of amonafide in central nervous system tumors

T2 - A Southwest Oncology Group Study

AU - Taylor, Sarah A.

AU - Rankin, Cathryn

AU - Townsend, Jeannette J.

AU - Craig, Johnny B.

AU - Vance, Ralph B.

AU - Solank, Dilip L.

AU - Brown, Thomas D.

AU - Jaeckle, Kurt

PY - 2002/4/6

Y1 - 2002/4/6

N2 - Amonafide 300 mg/M2 was administered intravenously on a daily × 5 schedule to 27 eligible patients with recurrent or progressive central nervous system tumors. There were no objective responses. The most common toxicities were gastrointestinal, hematologic and neurologic. Further study of amonafide in patients with central nervous system malignancies is not indicated.

AB - Amonafide 300 mg/M2 was administered intravenously on a daily × 5 schedule to 27 eligible patients with recurrent or progressive central nervous system tumors. There were no objective responses. The most common toxicities were gastrointestinal, hematologic and neurologic. Further study of amonafide in patients with central nervous system malignancies is not indicated.

KW - Amonafide

KW - Central nervous system tumors

UR - http://www.scopus.com/inward/record.url?scp=0036204930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036204930&partnerID=8YFLogxK

U2 - 10.1023/A:1014488922368

DO - 10.1023/A:1014488922368

M3 - Article

C2 - 12003186

AN - SCOPUS:0036204930

VL - 20

SP - 113

EP - 115

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 1

ER -

Access to Document

10.1023/A:1014488922368